Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

NCT01582672 is registered in ClinicalTrials.gov with Argos Therapeutics as lead sponsor.

NCT NCT01582672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01582672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
Lead sponsor
Argos Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2012
Completion date
April 30, 2018
Enrollment
462 (actual)
Sites
125

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma, metastatic renal cell carcinoma, renal cell carcinoma